| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 63 | 17.4x | 17.8x | Around median | |
Growth | 80 | 13.5% | 7.1% | Top tier | |
Quality | 81 | 11.3% | 4.5% | Top tier | |
Safety | 73 | 2.0x | 2.6x | Top tier | |
Capital Return | 70 | — | 2.12% | Top tier | |
Momentum | 2 | -52.6% | 2.9% | Bottom tier | |
Sentiment | 87 | 17 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Boston Scientific Corporation is a medical technology company that generates revenue from interventional devices and solutions spanning interventional cardiology and vascular therapies, cardiac rhythm management, electrophysiology, and WATCHMAN for left atrial appendage closure, as well as endoscopy, neuromodulation, urology, interventional oncology, and embolization. In fiscal Q2 2026, the main growth drivers were interventional cardiology, endoscopy, and neuromodulation, while businesses other than electrophysiology and WATCHMAN represented approximately 75% of revenue, and management expects them to grow by approximately 6% in the second half of fiscal 2026.
In fiscal Q2 2026, revenue reached $5.442 billion, up 7.5% on a reported basis and 7.0% on both an operational and organic basis compared with fiscal Q2 2025. Gross profit according to EDGAR was approximately $3.8 billion, equivalent to a gross margin of approximately 70.4%, while net income was $905 million and GAAP earnings per share were $0.61; on an adjusted basis, gross margin was 70.3%, operating margin was 28.4%, and earnings per share were $0.86, up 15%.
The performance mix was varied in fiscal Q2 2026: cardiovascular grew 8%, interventional cardiology 15%, vascular therapies 8%, neuromodulation and interventional oncology and embolization 12% each, and endoscopy 7%. By contrast, urology grew 1%, cardiac rhythm management declined 2%, while WATCHMAN slowed to 4% growth and electrophysiology grew 9%, with growth of only 3% in the United States versus 23% internationally.
The analyst consensus is “Buy,” with an average target of $66.5 and a wide range of $50 to $100; the average is approximately 39% below the 52-week range high of $109.5, while the highest target is approximately 9% below that high. No price-to-earnings ratio is available in the provided data, so the risk assessment rests on the breadth of the target range and the 52-week range of $42.2–$109.5, as well as the reduction in fiscal 2026 guidance and the expected pressure on WATCHMAN, electrophysiology, and margins.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
The reduction announced on July 29, 2026, was primarily driven by WATCHMAN and electrophysiology. The U.S. WATCHMAN market slowed because of changing patient identification and referral patterns following the publication of multiple sets of clinical evidence, while the market-share loss in U.S. electrophysiology was greater than management had expected. As a result, fiscal 2026 organic growth guidance is now 5%–6%, with adjusted earnings per share of $3.28–$3.32.
WATCHMAN grew 4% globally in fiscal Q2 2026, with international growth of 18% and U.S. growth of 3%. Concomitant procedures represented approximately one-third of U.S. WATCHMAN procedures and grew by more than 60%, but standalone procedures, which represent the remaining two-thirds, declined by a low-teens percentage compared with fiscal Q2 2025. Management expects the business to decline globally by a mid- to high-single-digit percentage in the second half of fiscal 2026.
Boston Scientific is targeting the launch of the SEISMIQ 4CE coronary catheter in the first half of fiscal 2027 following the positive results of the FRACTURE study. In electrophysiology, the company expects to launch FARAWAVE Ultra and enter the ICE market during fiscal 2027, followed by a contribution from FARAFLEX in fiscal 2028. It also expects to introduce the TIVUS renal denervation system in fiscal 2028, and management links these platforms to improved growth in fiscal 2028 and beyond.
Automated analysis for informational purposes only — not investment advice.
Revenue reached $5.442 billion, gross profit according to EDGAR was approximately $3.8 billion, and net income was $905 million. GAAP earnings per share were $0.61, while adjusted earnings per share were $0.86 and grew 15% compared with fiscal Q2 2025. Adjusted gross margin was 70.3% and adjusted operating margin was 28.4%, but the results benefited from favorable tax items.
Boston Scientific expects to close the Penumbra transaction in the second half of fiscal 2026 after completing the remaining regulatory approvals, and its current guidance does not include the transaction's impact. Management expects Penumbra to be slightly dilutive to operating margin and earnings per share in fiscal 2026, despite viewing its portfolio as complementary to the cardiovascular business over the long term. The company invested $1.5 billion in MiRus, including an exclusive option to acquire the SIEGEL TAVR valve assets if specified clinical and regulatory milestones are achieved.
The program targets approximately $500 million in annual operating savings upon exiting fiscal 2029. Management expects to realize more than half of the savings upon exiting fiscal 2027, with the effects appearing first in selling, general, and administrative expenses and then in cost of sales over time. The company intends to use the savings to improve efficiency and continue funding growth opportunities, supporting a return to meaningful operating-margin expansion and earnings-per-share growth in fiscal 2028 and beyond.
